Spero therapeutics reschedules fourth quarter and full year 2022 earnings release and conference call to march 30, 2023

Cambridge, mass., march 13, 2023 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that it has changed the date of its previously announced 2022 fourth quarter and full year earnings release and conference call from today, monday, march 13, 2023 to thursday, march 30, 2023. spero is still evaluating the accounting treatment associated with the gsk transaction in 2022 and needs additional time to complete its audit and file its annual report on form 10-k for the fiscal year ended december 31, 2022.
SPRO Ratings Summary
SPRO Quant Ranking